December 21, 2012

Critical Outcome Technologies Inc. Reports Fiscal 2013 Second Quarter Financial Results

December 13, 2012

COTI-2 Found to Correct Specific p53 Gene Mutation in Human Ovarian Cancer Cells

December 6, 2012

Critical Outcome Technologies Inc. Announces Drug Discovery Agreement with Multinational Pharmaceutical Company

October 9, 2012

Critical Outcome Technologies Inc. Achieves Important Milestone for AML Program

September 28, 2012

Critical Outcome Technologies Inc. Delivering Podium Presentation on New Mechanism of Action Data for COTI-2

September 26, 2012

Critical Outcome Technologies Inc. Provides Business and Scientific Update at Annual General Meeting

September 26, 2012

Critical Outcome Technologies Inc. Announces the Issuance of Stock Options

September 25, 2012

Annual General Meeting Presentation

September 21, 2012

Critical Outcome Technologies Inc. Reports Fiscal 2013 First Quarter Financial Results

September 20, 2012

Critical Outcome Technologies Inc. Announces Warrant Term Amendments

September 20, 2012

Critical Outcome Technologies Announces Important New Mechanism of Action Data for COTI-2

September 18, 2012

Critical Outcome Technologies Inc. Initiates Final Toxicity Studies for COTI-2

September 13, 2012

Critical Outcome Technologies Inc. Achieves Milestones Moving COTI-2 Closer to IND Filing

September 12, 2012

Critical Outcome Technologies and Delmar Chemicals Sign Collaboration Agreement to Identify and Develop Novel Small Molecules

September 11, 2012

Critical Outcome Technologies Inc. Issues Share Options

September 6, 2012

Critical Outcome Technologies Inc. and Western University Sign Commercial Collaboration Agreement

July 12, 2012

COTI Reports on Operational Successes and Financial Results

July 12, 2012

Critical Outcome Technologies Inc. Strengthens Board with New Director

June 15, 2012

Critical Outcome Technologies Inc. Presenting at the 2012 BIO International Convention

May 24, 2012

Critical Outcome Technologies Inc. Selected to Present CHEMSAS® as a Drug Discovery Platform

May 2, 2012

Critical Outcome Technologies Inc. Strengthens Management Resources

April 27, 2012

Critical Outcome Technologies Inc. Completes Financing

April 10, 2012

Critical Outcome Technologies Inc. Completes Financing

April 2, 2012

Critical Outcome Technologies Inc. Receives Second U.S. Patent for COTI-2

March 29, 2012

Critical Outcome Technologies Inc. Reports Fiscal 2012 Third Quarter Financial Results

March 26, 2012

Critical Outcome Technologies Inc. Completes First Tranche Financing

February 22, 2012

Critical Outcome Technologies Inc. Selected for Trade Mission to BioPartnering North America

February 14, 2012

Critical Outcome Technologies Inc. to Deliver Scientific Podium Presentation on COTI-2

February 8, 2012

Critical Outcome Technologies Inc. Initiates Development and Validation of Bioanalytical Method for COTI-2 Phase 1 Study

February 2, 2012

Critical Outcome Technologies Inc. Identifies Phase-1 Oral Formulation Candidates for COTI-2

January 24, 2012

Critical Outcome Technologies Inc. Initiates Preclinical Testing of AML Drug Candidates

January 9, 2012

Critical Outcome Technologies Inc. to Meet with Prospective Licensing Partners for COTI-2 at Biotech Showcase